CONTEXT: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. OBJECTIVES/ DESIGN: We conducted a randomized, double-masked, placebo-controlled, multicenter study to investigate the hormonal, body composition, and physical performance effects and the safety of the orally active GHS capromorelin in older adults with mild functional limitation. INTERVENTION/PARTICIPANTS: A total of 395 men and women aged 65-84 yr were randomized for an intended 2 yr of treatment to four dosing groups (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day) or placebo. Although the study was terminated early according to predetermined treatment effect criteria, 315 subjects completed 6 months of treatment, and 284 completed 12 months. RESULTS: A sustained dose-related rise in IGF-I concentrations occurred in all active treatment groups. Each capromorelin dose prompted a rise in peak nocturnal GH, which was greatest with the least frequent dosing. At 6 months, body weight increased 1.4 kg in subjects receiving capromorelin and decreased 0.2 kg in those receiving placebo (P = 0.006). Lean body mass increased 1.4 vs. 0.3 kg (P = 0.001), and tandem walk improved by 0.9 sec (P = 0.02) in the pooled treatment vs. placebo groups. By 12 months, stair climb also improved (P = 0.04). Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. CONCLUSIONS: In healthy older adults at risk for functional decline, administration of the oral GHS capromorelin may improve body composition and physical function.
RCT Entities:
CONTEXT: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. OBJECTIVES/ DESIGN: We conducted a randomized, double-masked, placebo-controlled, multicenter study to investigate the hormonal, body composition, and physical performance effects and the safety of the orally active GHS capromorelin in older adults with mild functional limitation. INTERVENTION/PARTICIPANTS: A total of 395 men and women aged 65-84 yr were randomized for an intended 2 yr of treatment to four dosing groups (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day) or placebo. Although the study was terminated early according to predetermined treatment effect criteria, 315 subjects completed 6 months of treatment, and 284 completed 12 months. RESULTS: A sustained dose-related rise in IGF-I concentrations occurred in all active treatment groups. Each capromorelin dose prompted a rise in peak nocturnal GH, which was greatest with the least frequent dosing. At 6 months, body weight increased 1.4 kg in subjects receiving capromorelin and decreased 0.2 kg in those receiving placebo (P = 0.006). Lean body mass increased 1.4 vs. 0.3 kg (P = 0.001), and tandem walk improved by 0.9 sec (P = 0.02) in the pooled treatment vs. placebo groups. By 12 months, stair climb also improved (P = 0.04). Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. CONCLUSIONS: In healthy older adults at risk for functional decline, administration of the oral GHS capromorelin may improve body composition and physical function.
Authors: Diego Perez-Tilve; Kristy Heppner; Henriette Kirchner; Sarah H Lockie; Stephen C Woods; David L Smiley; Matthias Tschöp; Paul Pfluger Journal: FASEB J Date: 2011-05-04 Impact factor: 5.191
Authors: Fred Sattler; Shalender Bhasin; Jiaxiu He; Chih-Ping Chou; Carmen Castaneda-Sceppa; Kevin Yarasheski; Ellen Binder; E Todd Schroeder; Miwa Kawakubo; Anqi Zhang; Ronenn Roubenoff; Stanley Azen Journal: J Gerontol A Biol Sci Med Sci Date: 2010-11-08 Impact factor: 6.053
Authors: William S Denney; Gabriele E Sonnenberg; Santos Carvajal-Gonzalez; Theresa Tuthill; V Margaret Jackson Journal: Br J Clin Pharmacol Date: 2016-10-29 Impact factor: 4.335